| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | serdemetan:SCH-529074 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |